SIBN at a glance
SI-BONE, Inc. (SIBN, SEC CIK 1459839) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), SI-BONE, Inc. (SIBN) reported revenue of $200.9 million (up 20.2% from FY2024) and a net loss of $18.9 million. Diluted EPS was -$0.44.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding SI-BONE, Inc. (SIBN) shares worth $229.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by FRANCIS LAURA on November 17, 2026 of 1,901 shares at $23.18 per share.
- In the last 90 days, SIBN insiders reported 0 open-market purchases ($0) and 31 open-market sales ($8.0M) on Form 4, a net sale of $8.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $200.9M
- +20.2% vs prior year
- Insiders · 90 days
- 0 buys · 31 sells
- Net −$8.0M
- 13F holders
- 25 funds
- $229.0M · −1 vs prior quarter
- Latest 8-K
- Nov 2, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $55.7M, up 14.5% YoY from $48.7M, driven by 19.5% procedure-volume growth
- Gross margin 79.3% vs 79.8% YoY, reflecting site-of-care and procedure-mix changes
- U.S. revenue $52.8M, up 13.9%; international revenue $2.9M, up 27.0%
- Operating cash flow $4.4M vs $(2.4)M YoY; investing outflow $13.1M, including $9.0M equipment purchases
- Cash and marketable securities $146.3M vs $147.8M at December 31, 2025; funding expected for next 12 months, with downturn and capital-market risks
Risk Factors
- New operational risk: tube packaging failure affected approximately 3,900 iFuse TORQ implants, including 98 voluntarily recalled units
- Regulatory risk: FDA Class II recall reporting followed potentially compromised sterility in iFuse TORQ implants
- Supply-chain risk: titanium availability and costs exposed to Russia-Ukraine disruptions and potential tariffs
- Product-liability risk: nonsterile packaging could increase infection risk and require revision surgery
- Manufacturing risk: limited-source components and contract sterilization constraints could disrupt product availability
AI summary of the SIBN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces SI-BONE results for the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, profitability, guidance and operating metrics influencing valuation
Item EX-99.1: Item EX-99.1
- Q3 revenue $55.7M, up 14.5%, with U.S. procedure volume growth of approximately 19.5% offset by lower average selling price
- Net loss narrowed 20.7% to $3.6M, while adjusted EBITDA rose 32.4% to $3.0M and operating cash flow reached $5.9M
Item 1.01: Entry into a Material Definitive Agreement
- Headquarters lease extended one month through October 31, 2026
- $43,696 October base rent for 21,848 square feet in Santa Clara
Item 8.01: Other Events
- Voluntary recall of 98 iFuse TORQ implants over packaging sterility-barrier failures and potential infection risk
- Two recalled implants were implanted; no infections or adverse events reported as of filing date
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 signals a new direct financial obligation, with terms contained in Item 1.01
- Investors should review the related agreement for amount, interest rate, maturity and borrowing purpose
Item 2.02: Results of Operations and Financial Condition
- SI-BONE announced financial results for the quarter ended June 30, 2026
- Full operating metrics, financial results and management commentary are in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $56.0M, up 15.2%, with U.S. procedure volume growth of 14.9%
- Adjusted EBITDA $2.8M versus $1.0M, while net loss narrowed to $4.1M from $6.2M
AI summaries of SIBN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SIBN
Don't miss the next SIBN filing
- Alerts as it files. A push when SIBN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SIBN, by share count.
- Ask anything. An AI agent that reads every SIBN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| FRANCIS LAURA | Sell | Nov 17, 2026 | 1,901 | $23.18 |
| Maheshwari Anshul | Sell | Nov 17, 2026 | 1,715 | $23.19 |
| FRANCIS LAURA | Sell | Nov 16, 2026 | 3,651 | $23.33 |
| Maheshwari Anshul | Sell | Nov 16, 2026 | 2,189 | $23.34 |
| FRANCIS LAURA | Sell | Nov 16, 2026 | 2,235 | $23.33 |
| FRANCIS LAURA | Sell | Nov 16, 2026 | 3,203 | $23.32 |
| PISETSKY MICHAEL A. | Sell | Nov 16, 2026 | 1,871 | $23.31 |
| PISETSKY MICHAEL A. | Sell | Nov 16, 2026 | 1,854 | $23.32 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $167.2M | $200.9M |
| Gross Profit | - | $132.1M | $159.9M |
| Operating Income | - | -$35.2M | -$22.3M |
| Net Income | - | -$30.9M | -$18.9M |
| Gross Margin | - | 79.0% | 79.6% |
| Op. Margin | - | -21.1% | -11.1% |
| Net Margin | - | -18.5% | -9.4% |
| Balance Sheet | |||
| Total Assets | $230.4M | $230.4M | $238.6M |
| Equity | - | $167.0M | $177.5M |
| ROE | - | -18.5% | -10.6% |
| Per Share | |||
| EPS | - | $-0.75 | $-0.44 |
| Cash Flow | |||
| Operating CF | - | -$12.4M | -$675K |
| CapEx | $7.8M | $10.5M | $8.4M |
Source: XBRL data in SI-BONE, Inc. (SIBN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SIBN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $229.0M |
| Q2 2026 | 26 | $178.1M |
| Q1 2026 | 28 | $143.5M |
| Q4 2025 | 25 | $218.5M |
| Q3 2025 | 25 | $164.5M |
| Q2 2025 | 25 | $207.4M |
| Q1 2025 | 22 | $92.7M |
| Q4 2024 | 17 | $70.6M |
- Millennium Management+562.7K (+154%)
- Morgan Stanley+123.5K (+94%)
- D.E. Shaw & Co+122.5K (+66%)
- Citigroup+80.5K (+89%)
- Vanguard Capital Management LLC+52.0K (+3%)
- Wells Fargo & Co−27.0K (-66%)
- Allstate−13.0K (-47%)
- Raymond James Financial−3.7K (-20%)
- Invesco Ltd−3.5K (-6%)
- PNC Financial Services−1.9K (-70%)
- Citadel Advisors LLC+186.5K
- Prudential Financial+54.5K
- Renaissance Technologies LLC−44.1K
- Franklin Resources−34.2K
- FMR LLC (Fidelity)−3.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 193 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SIBN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Oct 14, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Sep 11, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
SIBN SEC filings: frequently asked questions
Are SIBN insiders buying or selling?
In the last 90 days, SI-BONE, Inc. (SIBN) officers, directors and 10% owners reported no open-market purchases and 31 open-market sales worth $8.0 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SIBN stock?
As of September 30, 2026, the largest SI-BONE, Inc. (SIBN) holders among the 13F filers tracked by SignalX were BlackRock ($70.0 million), Vanguard Capital Management LLC ($35.5 million), State Street Corp ($23.4 million), Millennium Management ($17.4 million), Dimensional Fund Advisors ($13.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SIBN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), SI-BONE, Inc. (SIBN) reported revenue of $200.9 million (up 20.2% from FY2024) and a net loss of $18.9 million. Diluted EPS was -$0.44. The figures come from the XBRL data in the 10-K.
What did SIBN report in its latest 8-K?
SI-BONE, Inc. (SIBN) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces SI-BONE results for the quarter ended September 30, 2026.
What are the latest SIBN SEC filings?
SI-BONE, Inc. (SIBN) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 18, 2026.
What is SIBN's SEC CIK number?
SI-BONE, Inc. (SIBN)'s SEC Central Index Key (CIK) is 1459839. EDGAR lists every SIBN filing under that number.
Ask anything about SIBN
The research agent reads SIBN's filings, financials, insider trades and 13F holders, then answers with sources.